These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 29394989)

  • 1. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
    Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
    Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
    Guidugli L; Pankratz VS; Singh N; Thompson J; Erding CA; Engel C; Schmutzler R; Domchek S; Nathanson K; Radice P; Singer C; Tonin PN; Lindor NM; Goldgar DE; Couch FJ
    Cancer Res; 2013 Jan; 73(1):265-75. PubMed ID: 23108138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
    Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
    Hu C; Huang H; Na J; Lumby C; Abozaid M; Holdren MA; Rao TJ; Karam R; Pesaran T; Weyandt JD; Csuy CM; Seelaus CA; Young CC; Fulk K; Heidari Z; Morais Lyra PC; Couch RE; Persons B; Polley EC; Gnanaolivu RD; Boddicker NJ; Monteiro ANA; Yadav S; Domchek SM; Richardson ME; Couch FJ
    Am J Hum Genet; 2024 Mar; 111(3):584-593. PubMed ID: 38417439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
    Hart SN; Hoskin T; Shimelis H; Moore RM; Feng B; Thomas A; Lindor NM; Polley EC; Goldgar DE; Iversen E; Monteiro ANA; Suman VJ; Couch FJ
    Genet Med; 2019 Jan; 21(1):71-80. PubMed ID: 29884841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
    Richardson ME; Hu C; Lee KY; LaDuca H; Fulk K; Durda KM; Deckman AM; Goldgar DE; Monteiro ANA; Gnanaolivu R; Hart SN; Polley EC; Chao E; Pesaran T; Couch FJ
    Am J Hum Genet; 2021 Mar; 108(3):458-468. PubMed ID: 33609447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
    Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
    BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
    Tram E; Savas S; Ozcelik H
    PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Khan MA; Varma AK
    J Biomol Struct Dyn; 2023 Nov; 41(19):9879-9889. PubMed ID: 36404616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
    Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
    J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
    Toland AE; Andreassen PR
    J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curated multiple sequence alignment for the Adenomatous Polyposis Coli (APC) gene and accuracy of in silico pathogenicity predictions.
    Karabachev AD; Martini DJ; Hermel DJ; Solcz D; Richardson ME; Pesaran T; Sarkar IN; Greenblatt MS
    PLoS One; 2020; 15(8):e0233673. PubMed ID: 32750050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
    Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
    J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional assays for classification of BRCA2 variants of uncertain significance.
    Farrugia DJ; Agarwal MK; Pankratz VS; Deffenbaugh AM; Pruss D; Frye C; Wadum L; Johnson K; Mentlick J; Tavtigian SV; Goldgar DE; Couch FJ
    Cancer Res; 2008 May; 68(9):3523-31. PubMed ID: 18451181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional assays for analysis of variants of uncertain significance in BRCA2.
    Guidugli L; Carreira A; Caputo SM; Ehlen A; Galli A; Monteiro AN; Neuhausen SL; Hansen TV; Couch FJ; Vreeswijk MP;
    Hum Mutat; 2014 Feb; 35(2):151-64. PubMed ID: 24323938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
    Jimenez-Sainz J; Jensen RB
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.